Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety Study: A Multi-Center, Double-Masked Phase 3 Safety Study Evaluation of the Long-Term Safety of LNZ101 in Presbyopic Subjects

Next Previous
Trial Profile

Safety Study: A Multi-Center, Double-Masked Phase 3 Safety Study Evaluation of the Long-Term Safety of LNZ101 in Presbyopic Subjects

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 27 Apr 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aceclidine (Primary) ; Aceclidine/brimonidine (Primary)
  • Indications Presbyopia
  • Focus Adverse reactions; Registrational
  • Acronyms CLARITY-3
  • Sponsors LENZ Therapeutics

Most Recent Events

  • 20 Apr 2026 According to a LENZ Therapeutics media release, company announced that it has submitted a Marketing Authorization Application (MAA) to the United Kingdoms Medicines and Healthcare products Regulatory Agency (MHRA) for the review and approval of VIZZ (aceclidine ophthalmic solution) for the treatment of presbyopia in adults.
  • 10 Mar 2026 According to a LENZ Therapeutics media release, based on positive data from CLARITY trials,the company has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for the review and approval of VIZZ for the treatment of presbyopia in adults.
  • 01 Dec 2025 According to a LENZ Therapeutics media release, based on positive data from (CLARITY-1,CLARITY-2 AND CLARITY-3 ) trials, a New Drug Application (NDA) to the Ministry of Food and Drug Safety (MFDS) for the review and approval of VIZZTM, for the treatment of presbyopia in adults in South Korea.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top